Hanmi’s Once Weekly Efpeglenatide Bests Liraglutide In Phase II
This article was originally published in PharmAsia News
Executive Summary
In its ongoing push to seek a global partner for its diabetes therapies, South Korea's major pharma firm Hanmi has presented the results of Phase IIb study for a once weekly form of its diabetes therapy efpeglenatide, which showed benefits over Novo Nordisk’s rival therapy Victoza.